5'-Desoxy-5'-N-morpholinoadenosin | 70178-22-2

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 5'-脱氧核糖核苷
• 英文名称: 5'-Desoxy-5'-N-morpholinoadenosin
• 英文别名: 5'-morpholin-4-yl-5'-deoxy-adenosine；(2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(morpholin-4-ylmethyl)oxolane-3,4-diol
• CAS: 70178-22-2
• 化学式: C₁₄H₂₀N₆O₄
• 分子量: 336.351
• InChiKey: ZYIZAKXANBARCW-IDTAVKCVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  132
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  吗啉 、 5'-氯-5'-脱氧腺苷 生成 5'-Desoxy-5'-N-morpholinoadenosin
  参考文献：
  名称：

  Vuilhorgne,M. et al., Heterocycles, 1978, vol. 11, p. 495 - 520

  摘要：

  DOI：

文献信息

• Combination therapies for treating methylthioadenosine phosphorylase deficient cells
  申请人：——

  公开号：US20040043959A1

  公开（公告）日：2004-03-04

  The present invention is directed to combination therapies for treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an inhibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase (“GARFT”) and/or aminoinidazolecarboximide ribonucleotide formyltransferase (“AICARFT”), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or “MTA”), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.

  本发明涉及用于治疗哺乳动物中与甲基硫腺苷磷酸化酶（MTAP）缺乏细胞相关的细胞增殖性疾病的联合疗法。该联合疗法通过给予新生核苷酸合成抑制剂和给予抗毒性剂，选择性地杀死MTAP缺乏细胞，其中，新生核苷酸合成抑制剂是甘氨酰核苷酸甲酰转移酶（“GARFT”）和/或氨基咪唑羧酰核苷酸甲酰转移酶（“AICARFT”）的抑制剂，抗毒性剂是MTAP底物（例如，甲基硫腺苷或“MTA”），MTA的前体，MTA前体的类似物或MTAP底物的前药。
• COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS
  申请人：PFIZER INC.

  公开号：EP1482977A1

  公开（公告）日：2004-12-08
• [EN] COMBINATION THERAPIES FOR TREATING METHYLTHIOADENOSINE PHOSPHORYLASE DEFICIENT CELLS<br/>[FR] POLYTHERAPIES POUR TRAITER DES CELLULES A DEFICIENCE EN METHYLTHIOADENOSINE PHOSPHORYLASE
  申请人：PFIZER

  公开号：WO2003074083A1

  公开（公告）日：2003-09-12

  The present invention is directed to combination therapies fro treating cell proliferative disorders associated with methylthioadenosine phosphorylase (MTAP) deficient cells in a mammal. The combination therapies selectively kill MTAP-deficient cells by administering an ihibitor of de novo inosinate synthesis and administering an anti-toxicity agent, wherein the inhibitors of de novo inosinate synthesis are inhibitors of glycinamide ribonucleotide formyltransferase ('GARFT') and/or aminoinidazolecarboximide ribonucleotide formyltransferase ('AICARFT'), and the anti-toxicity agent is an MTAP substrate (e.g. methylthioadenosine or 'MTA'), a precursor of MTA, an analog of an MTA precursor or a prodrug of an MTAP substrate.
• Vuilhorgne,M. et al., Heterocycles, 1978, vol. 11, p. 495 - 520
  作者：Vuilhorgne,M. et al.

  DOI：——

  日期：——